September 1, 2016 10:03 AM EDT
News Briefing

Pro­to­cols: No­vo chief Sørensen is hand­ing over the reins ear­ly; Cy­to­ki­net­ics moves Am­gen-part­nered heart drug in­to PhI­II

John Carroll

Editor & Founder

No­vo Nordisk CEO Lars Re­bi­en Sørensen wasn’t your typ­i­cal phar­ma CEO. Con­fi­dent in his com­pa­ny’s abil­i­ties, he al­so wasn’t too thin skinned about po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times